Efficacy of infliximab in neuro-Behçet’s disease presenting with isolated longitudinally extensive transverse myelitis

Kuroda, Ryo; Suzuki, Junko; Muramatsu, M; Tasaki, A.; Yano, Mariko; Imai, Noboru; Serizawa, Masahiro; Kobari, Masahiro

doi:10.1007/s00415-013-7150-5

Cited by 11 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with previous studies. [1][2][3][4][5][6] In most SCIs assessed in the present study, sagittal images showed longitudinally extensive involvement of the spinal cord, and axial images revealed preferential involvement of the central area with extensive lesions. Two patients had recurrent attacks.…”

Section: Discussionmentioning

confidence: 68%

“…There is only a handful of reports regarding SCI in NBD. [2][3][4][5][6] Although a few recent case reports demonstrated longitudinally extensive transverse myelitis (LETM) and negative results of anti-aquaporin-4 antibody assay in patients with SCI in NBD, there is still a shortage of information about magnetic resonance imaging (MRI) findings and serum anti-aquaporin-4 antibody assay. Thus, the present paper describes the clinical, laboratory and imaging characteristics of SCI in NBD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Spinal cord involvement in Behçet’s disease

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Introductionmentioning

confidence: 99%

Spinal cord involvement in Behçet’s disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A total of 21 studies that directly addressed the effectiveness of therapy for neuro-Behc¸et's disease met the study eligibility criteria and were included in the qualitative and quantitative analysis (Figure 1 and Table 1). 8,9,[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] The publications included two studies that investigated the effectiveness of infliximab in patients with multi-organ refractory Behc¸et's disease and satisfied the inclusion criteria (Hibi et al, 2016, andGiardina et al, 2011). 16,18 These studies were enrolled by the reviewers since they satisfied the inclusion criteria and presented objective measures to elicit the response of the neurological manifestations to infliximab therapy.…”

Section: Resultsmentioning

confidence: 99%

The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet’s disease: a systematic review and meta-analysis

Mohammed

Woldeamanuel

2023

J Int Med Res

View full text Add to dashboard Cite

Objective To study the effectiveness of infliximab for the treatment of refractory central neuro-Behçet’s disease. Methods In this systematic review and meta-analysis, the research question was designed using the ‘Population, Intervention, Comparator, and Outcomes’ (PICO) model and the search methodology was developed according to the PRISMA statement. The study was registered on PROSPERO. Web of Science, PubMed, and Cochrane Library databases were searched for articles published in English between January 2000 and January 2020. Data were analysed using Meta-Essentials software, version 10.12. Treatment effect size was determined by a random effects model. Interstudy heterogeneity was explored using I2 statistics. Cumulative meta-analysis was conducted to assess the temporal trend for accumulating evidence. Results Twenty-one studies, comprising 64 patients (mean age, 38 .21 years and mean disease duration, 84.76 months) were included. Effect-size analysis showed that 93.7% of the treated patients in the analysis were responders to infliximab therapy (95% confidence interval 0.88, 0.993). There was no significant inter-study heterogeneity (I2 = 0%). Cumulative analysis showed accumulating evidence favoring increasing effectiveness over the last 20 years. Conclusion Infliximab showed considerable therapeutic effectiveness in the treatment of refractory neuro-Behçet’s disease.

show abstract

“…Serum TNF (tumor necrosis factor)-α is increased in active BD [ 11 , 12 , 13 , 14 ]. TNF-α antagonist therapy, such as with infliximab, has shown significant improvements in various manifestations of BD [ 11 , 12 , 13 , 14 ]. Patient 2 dramatically improved in spite of the poor prognosis associated with spinal cord involvement in NBD.…”

Section: Discussionmentioning

confidence: 99%

“…Patient 2 failed to respond to a high dose of steroid treatment but showed a good response to infliximab. Serum TNF (tumor necrosis factor)-α is increased in active BD [11][12][13][14]. TNF-α antagonist therapy, such as with infliximab, has shown significant improvements in various manifestations of BD [11][12][13][14].…”

Section: Discussionmentioning

confidence: 99%

Two Cases of Probable Neuro-Behçet’s Disease with Longitudinally Extensive Transverse Myelitis

et al. 2021

View full text Add to dashboard Cite

We report 2 cases of probable neuro-Behçet’s disease (NBD) with longitudinally extensive transverse myelitis (LETM). In both cases, the patients presented paraplegia, as well as sensory, bladder, and rectal disturbances. Magnetic resonance imaging (MRI) of patient 1 showed continuous high signal intensity extending from the midbrain to the entire spinal cord in the central part of the cord on T2-weighted imaging (T2WI). Spinal MRI of patient 2 revealed high signal intensity extending from Th2 to Th10 in the central part of the cord on T2WI. Both patients received high-dose methylprednisolone. A continuous lesion from the midbrain to the entire spinal cord as in patient 1 has not been previously reported. Patient 2 dramatically improved by infliximab therapy. The present cases suggest that NBD should be considered as a differential diagnosis in patients with LETM.

show abstract

Efficacy of infliximab in neuro-Behçet’s disease presenting with isolated longitudinally extensive transverse myelitis

Cited by 11 publications

References 12 publications

Spinal cord involvement in Behçet’s disease

Spinal cord involvement in Behçet’s disease

The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet’s disease: a systematic review and meta-analysis

Two Cases of Probable Neuro-Behçet’s Disease with Longitudinally Extensive Transverse Myelitis

Contact Info

Product

Resources

About